Real Reports Q1 Revenue of $465.6M, Acquires RE/MAX
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy REAX?
Reports Q1 revenue $465.6M, consensus $481.87M. "Real delivered another quarter of significant growth, with revenue increasing 32% year-over-year, demonstrating the continued strength of our platform and agent value proposition," said Tamir Poleg, Chairman and Chief Executive Officer. "The agreement to acquire RE/MAX Holdings Inc. represents a defining moment in our history and in our industry - by combining Real's technology-driven brokerage with one of the industry's most iconic and trusted brands we will create the preeminent real estate platform of the future."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REAX
Wall Street analysts forecast REAX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.230
Low
6.00
Averages
7.00
High
8.00
Current: 2.230
Low
6.00
Averages
7.00
High
8.00
About REAX
The Real Brokerage Inc. is a real estate technology company that operates as a software-based brokerage across approximately 50 states in United Stated, the District of Columbia, and four Canadian provinces. Its platform leverages artificial intelligence (AI) and automation to enhance agent productivity while maintaining a lean operating model. The Company operates as a fully digital brokerage, offering agents a more flexible, efficient, and financially compelling model. Its technology platform is reZEN, is a proprietary transaction management and brokerage operations software. The Company’s services include end-to-end transaction management, automated compliance & brokerage oversight, integrated payment & financial services, Leo CoPilot: AI-powered agent support, and open application programming interface (API) for customization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE:OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may involve breaches of fiduciary duties impacting shareholder confidence and company reputation.
- RE/MAX Transaction Scrutiny: The sale of RE/MAX Holdings, Inc. (NYSE:RMAX) to The Real Brokerage Inc. offers either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers, prompting shareholders to consider their rights and options.
- XOMA Transaction Risks: XOMA Royalty Corporation (NASDAQ:XOMA) is involved in a sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC possibly seeking increased compensation for shareholders, affecting the future shareholder structure of the company.
- Merger Impact Analysis: The merger between The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX will result in Real shareholders owning approximately 59% of the combined entity, potentially altering the competitive landscape and necessitating a reassessment of shareholder rights and risks post-merger.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
Real Brokerage Confirms Acquisition of RE/MAX for $880M
- Transaction Value Confirmation: Real Brokerage (REAX) has confirmed the acquisition of RE/MAX (RMAX) for an enterprise value of approximately $880 million, representing a fully synergized multiple of 7x 2025 EBITDA, which is expected to enhance Real's profitability and adjusted EBITDA margin.
- Shareholder Options: RE/MAX shareholders can elect to receive either 5.15 shares of Real REMAX Group or $13.80 in cash per share, with total cash proceeds to RE/MAX investors expected to be no less than $60 million and no greater than $80 million, demonstrating strong appeal to shareholders.
- Post-Merger Structure: Following the merger, Real shareholders are expected to own about 59% of the new entity, while RE/MAX investors will hold approximately 41%, with the new company named Real REMAX Group and set to trade on NASDAQ, further enhancing market competitiveness.
- Business Synergies: The acquisition is anticipated to generate about $30 million in annual run-rate cost savings, combining Real's brokerage platform with RE/MAX's expansive global franchise network, resulting in a robust team of approximately 8,500 franchisees and over 180,000 agents, driving future business growth.
See More
RE/MAX Merges with The Real Brokerage, Creating Real REMAX Group
- Shareholder Options: RE/MAX shareholders can choose to receive either 5.152 shares of the new company or $13.80 in cash per share, representing a roughly 72% premium over Friday's closing price, indicating strong market confidence in the merger and expected enhancement of shareholder value.
- Leadership Structure: Tamir Poleg, the current CEO of The Real Brokerage, will serve as chairman and CEO of the merged entity, Real REMAX Group, which is expected to leverage its AI-driven brokerage model alongside RE/MAX's established global franchise network to enhance operational efficiency.
- Financial Outlook: The merger is projected to generate approximately $2.3 billion in annual revenue and $157 million in adjusted earnings on a pro forma basis by 2025, indicating that the merger will significantly boost the company's profitability and margins, thereby strengthening its competitive position.
- Positive Market Reaction: Following the merger announcement, RE/MAX shares surged over 20% in pre-market trading, reflecting investor optimism about the merger, while shareholder expectations for future growth continue to rise.
See More
RE/MAX Stock Surges 15% on $550M Sale to The Real Brokerage
- Stock Surge: RE/MAX (RMAX) shares jumped approximately 15% during pre-market trading on Monday, reflecting market optimism regarding its impending sale to tech-focused real estate firm The Real Brokerage (REAX) valued at $550 million.
- Significant Transaction Value: The deal is estimated at around $550 million, with total transaction value, including debt, projected to reach approximately $880 million, underscoring RE/MAX's strong position and appeal in the real estate market.
- Shareholder Options: RE/MAX shareholders will have the option to receive either 5.15 shares of the new combined entity or $13.80 in cash for each share they own, a flexible choice that is likely to attract more investor participation and bolster shareholder confidence.
- Post-Merger Leadership: The combined entity will be led by Real Brokerage CEO Tamir Poleg as chairman and CEO, while both the RE/MAX and Real brands will continue to operate, ensuring the continuity of brand value and market influence.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE:OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may involve breaches of fiduciary duties impacting shareholder confidence and company reputation.
- RE/MAX Transaction Scrutiny: The sale of RE/MAX Holdings, Inc. (NYSE:RMAX) to The Real Brokerage Inc. offers either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers, prompting shareholders to consider their rights and options.
- XOMA Transaction Risks: XOMA Royalty Corporation (NASDAQ:XOMA) is involved in a sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC possibly seeking increased compensation for shareholders, affecting the future shareholder structure of the company.
- Merger Impact Analysis: The merger between The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX will result in Real shareholders owning approximately 59% of the combined entity, potentially altering the competitive landscape and necessitating a reassessment of shareholder rights and risks post-merger.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
Real Brokerage Confirms Acquisition of RE/MAX for $880M
- Transaction Value Confirmation: Real Brokerage (REAX) has confirmed the acquisition of RE/MAX (RMAX) for an enterprise value of approximately $880 million, representing a fully synergized multiple of 7x 2025 EBITDA, which is expected to enhance Real's profitability and adjusted EBITDA margin.
- Shareholder Options: RE/MAX shareholders can elect to receive either 5.15 shares of Real REMAX Group or $13.80 in cash per share, with total cash proceeds to RE/MAX investors expected to be no less than $60 million and no greater than $80 million, demonstrating strong appeal to shareholders.
- Post-Merger Structure: Following the merger, Real shareholders are expected to own about 59% of the new entity, while RE/MAX investors will hold approximately 41%, with the new company named Real REMAX Group and set to trade on NASDAQ, further enhancing market competitiveness.
- Business Synergies: The acquisition is anticipated to generate about $30 million in annual run-rate cost savings, combining Real's brokerage platform with RE/MAX's expansive global franchise network, resulting in a robust team of approximately 8,500 franchisees and over 180,000 agents, driving future business growth.
See More
RE/MAX Merges with The Real Brokerage, Creating Real REMAX Group
- Shareholder Options: RE/MAX shareholders can choose to receive either 5.152 shares of the new company or $13.80 in cash per share, representing a roughly 72% premium over Friday's closing price, indicating strong market confidence in the merger and expected enhancement of shareholder value.
- Leadership Structure: Tamir Poleg, the current CEO of The Real Brokerage, will serve as chairman and CEO of the merged entity, Real REMAX Group, which is expected to leverage its AI-driven brokerage model alongside RE/MAX's established global franchise network to enhance operational efficiency.
- Financial Outlook: The merger is projected to generate approximately $2.3 billion in annual revenue and $157 million in adjusted earnings on a pro forma basis by 2025, indicating that the merger will significantly boost the company's profitability and margins, thereby strengthening its competitive position.
- Positive Market Reaction: Following the merger announcement, RE/MAX shares surged over 20% in pre-market trading, reflecting investor optimism about the merger, while shareholder expectations for future growth continue to rise.
See More
RE/MAX Stock Surges 15% on $550M Sale to The Real Brokerage
- Stock Surge: RE/MAX (RMAX) shares jumped approximately 15% during pre-market trading on Monday, reflecting market optimism regarding its impending sale to tech-focused real estate firm The Real Brokerage (REAX) valued at $550 million.
- Significant Transaction Value: The deal is estimated at around $550 million, with total transaction value, including debt, projected to reach approximately $880 million, underscoring RE/MAX's strong position and appeal in the real estate market.
- Shareholder Options: RE/MAX shareholders will have the option to receive either 5.15 shares of the new combined entity or $13.80 in cash for each share they own, a flexible choice that is likely to attract more investor participation and bolster shareholder confidence.
- Post-Merger Leadership: The combined entity will be led by Real Brokerage CEO Tamir Poleg as chairman and CEO, while both the RE/MAX and Real brands will continue to operate, ensuring the continuity of brand value and market influence.
See More
